Evotec

2Q Revenues: €38.0 million (+14%)

2Q Earnings: €3.9 million (-73%)

YTD Revenues: €75.5 million (+37%)

YTD Earnings: €2.7 million (-80%)

Comments: Growth was driven by the EVT Execute business (up 35% to €79.8 million), the contribution of the Sanofi collaboration as well as milestone achievements. R&D expenses for the first half increased 6% to €9.0 million. Results include one-time effects with regards to the bargain purchase resulting from the acquisition of Evotec (France) SAS in 2015.